Point-of-care testing: a cardiologist's view

被引:15
作者
Stubbs, P [1 ]
Collinson, PO
机构
[1] Univ London St Georges Hosp, Dept Chem Pathol, London SW17 0QT, England
[2] Mayday Hosp, Dept Cardiol, Surrey, England
关键词
turnaround time; therapeutic decisions; cardiac troponins; outcomes; length of stay;
D O I
10.1016/S0009-8981(01)00560-5
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The rationale for point-of-care testing is that more rapid provision of biochemical test results performed at the patients bedside will equate with better outcomes. For this to be the case, a number of conditions must be satisfied, and in particular the choice of appropriate markers, an adequate turnaround time (TAT), and an accurate measurement. Point-of-care testing of cardiac markers was found to reduce TAT from 72 (central laboratory) to 20 min thus allowing to decrease total hospital stay. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:57 / 61
页数:5
相关论文
共 40 条
  • [1] DIAGNOSIS OF PERIOPERATIVE MYOCARDIAL-INFARCTION WITH MEASUREMENT OF CARDIAC TROPONIN-I
    ADAMS, JE
    SICARD, GA
    ALLEN, BT
    BRIDWELL, KH
    LENKE, LG
    DAVILAROMAN, VG
    BODOR, GS
    LADENSON, JH
    JAFFE, AS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (10) : 670 - 674
  • [2] [Anonymous], 1987, Lancet, V2, P871
  • [3] [Anonymous], 1988, Lancet, V1, P545
  • [4] [Anonymous], 1994, Circulation, V89, P1545
  • [5] [Anonymous], 1988, LANCET, V2, P349
  • [6] Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes
    Antman, EM
    Tanasijevic, MJ
    Thompson, B
    Schactman, M
    McCabe, CH
    Cannon, CP
    Fischer, GA
    Fung, AY
    Thompson, C
    Wybenga, D
    Braunwald, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (18) : 1342 - 1349
  • [7] INDICATIONS FOR FIBRINOLYTIC THERAPY IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - COLLABORATIVE OVERVIEW OF EARLY MORTALITY AND MAJOR MORBIDITY RESULTS FROM ALL RANDOMIZED TRIALS OF MORE THAN 1000 PATIENTS
    APPLEBY, P
    BAIGENT, C
    COLLINS, R
    FLATHER, M
    PARISH, S
    PETO, R
    BELL, P
    HALLS, H
    MEAD, G
    DIAZ, R
    PAOLASSO, E
    PAVIOTTI, C
    ROMERO, G
    CAMPBELL, T
    OROURKE, MF
    THOMPSON, P
    LESAFFRE, E
    VANDEWERF, F
    VERSTRAETE, M
    ARMSTRONG, PW
    CAIRNS, JA
    MORAN, C
    TURPIE, AG
    YUSUF, S
    GRANDE, P
    HEIKKILA, J
    KALA, R
    BASSAND, JP
    BOISSEL, JP
    BROCHIER, M
    LEIZOROVICZ, A
    BRUGGEMANN, T
    KARSCH, KR
    KASPER, W
    LAMMERTS, D
    NEUHAUS, KL
    MEYER, J
    SCHRODER, R
    VONESSEN, R
    SARAN, RK
    ARDISSINO, D
    BONADUCE, D
    BRUNELLI, C
    CERNIGLIARO, C
    FORESTI, A
    FRANZOSI, MG
    GUIDUCCI, D
    MAGGIONI, A
    MAGNANI, B
    MATTIOLI, G
    [J]. LANCET, 1994, 343 (8893) : 311 - 322
  • [8] ARTNERDWORZAK E, 1990, CLIN CHEM, V36, P1853
  • [9] Cardiac troponin I does not increase after cardioversion
    Bonnefoy, E
    Chevalier, P
    Kirkorian, G
    Guidolet, J
    Marchand, A
    Touboul, P
    [J]. CHEST, 1997, 111 (01) : 15 - 18
  • [10] Braun SL, 2000, CLIN CHEM, V46, P279